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ABSTRACT 
The aim of the study was to determine the place and role of serologic methods in 
detecting Helicobacter pylori (H. pylori) infection, on the basis of estimated enzyme-
linked immunosorbent assay (ELISA) and complement fixation test (CFT) sensitivity and 
specificity. A total of 549 patients were included in the study. ELISA and CFT as 
serologic methods were compared with invasive methods (rapid urease test – CLO test, 
culture, histology). The sensitivity of serologic methods was above 90%, and their 
specificity was around 80%. Study results confirmed the value, reliability and usefulness 
of serologic methods in the detection of H. pylori infection. 
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Introduction 
Helicobacter pylori (H. pylori), a bacterium that marked the 20th century, is the most 
common etiologic factor of peptic ulcer, especially in duodenum1-6. It is associated with 
non-cardiac carcinoma of the stomach (diffuse and intestinal type)7, and its association 
with some extraintestinal diseases has also been postulated8-10. Diagnostic methods for 
the detection of H. pylori infection are divided into two groups: invasive and 
noninvasive11. All invasive methods are based on endoscopy with biopsy samples of 
gastric mucosa obtained for direct (histology and culture) or indirect (rapid urease test) 
diagnosis. 
Rapid urease test or CLO test has a sensitivity of 90%-95% and specificity of 98%. In 
90% of patients with negative CLO test gastric mucosa is usually unchanged. However, 
5%-10% of tested samples can be CLO negative because of inadequate number of the 
bacteria present in the sample12-14. 
Histology is a rapid, reliable and reproducible method. This method can also be used to 
determine the morphological characteristics of gastritis. The sensitivity and specificity of 
the method are around 95%13,15,16. Culture requires a gastric mucosa biopsy sample; 
however, at least two samples (antrum/corpus) are needed due to uneven colonization of 
gastric mucosa. This is particularly important on taking samples for the control of H. 
pylori eradication. The sensitivity of culture is 90%-95% and specificity around 
100%13,17. In addition to identifying the strain of H. pylori, molecular methods are used to 
determine the genes responsible for different factors of virulence6,13. 
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Noninvasive methods are based on the detection of urease activity (urea breath test), 
presence of specific antibodies in serum and/or saliva of infected person (serology), and 
in recent time on antigen detection in stool. 
Urea breath test detects the presence of H. pylori in stomach by detecting the H. pylori 
urease. This test has a high sensitivity and specificity (95%-98% both)13,18,19. Urea breath 
test is usually used to prove H. pylori eradication at 4 weeks of antimicrobial therapy 
completion. 
H. pylori induces inflammatory reactions in gastric mucosa, thus activating specific 
humoral immunity response, which in turn results in the production of specific IgM, IgA 
and IgG antibodies. Specific IgM antibodies are produced in a minority of infected 
persons. They are specific but difficult to detect. The sensitivity of tests for the detection 
of specific IgA antibodies, which are bound to the surface of the bacteria and prevent 
their adhesion to the cells, is 60%-80%. Specific IgG antibodies, subclasses IgG1, IgG2 
and IgG4, are most commonly present in the serum of infected individuals. The tests used 
for their detection have a high sensitivity (94%) and specificity (98%), and are most 
commonly used in the diagnosis of H. pylori infection. During the course of infection, the 
levels of antibodies are insignificantly changed20,21. Different serologic tests are used to 
detect H. pylori infection: agglutination, latex agglutination, passive hemagglutination, 
complement fixation test (CFT), enzyme-linked immunosorbent assay (ELISA) and 
immunoblot test22. Serologic diagnosis has a special place in epidemiological studies23. 
Since recently, immunoenzyme procedures have been used for direct detection of H. 
pylori antigen in stool sample. These procedures are used to detect active infection as 
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well as its eradication. The procedure sensitivity is 80%-90% and specificity around 
100%17-23. 
The aim of this study was to determine the place and role of serologic methods in the 
diagnosis of H. pylori infection, on the basis of estimated ELISA and CFT sensitivity and 
specificity.   
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Materials and Methods 
The study was performed during the 1994-2002 period at Merkur University Hospital and 
Prison Infirmary in Zagreb, and included 549 patients (Table 1): 436 patients (M/F 
250/186, mean age 53.4 years) regularly attending Endoscopy Laboratory, Merkur 
University Hospital, and 113 patients (M/F 102/11, mean age 41.9 years) from Prison 
Infirmary. All patients suffered pain in the upper abdomen with dyspeptic symptoms. 
Prior to entering the study, the patients signed the informed consent form for gastroscopy. 
The study design was approved by the Hospital Ethics Committee. 
TABLE 1. 
PATIENT GENERAL CHARACTERISTICS 
       N 
  Mean age (χ) 
        (yrs) 
Merkur University Hospital patients     436         53.4 
               - men     250         53.2 
               - women     186         54.1 
Prison Infirmary patients     113         41.9 
               - men     102         42.2 
               - women       11         40.0 
Total     549         51.8 
N-number of patients 
 
Study patients underwent clinical examination and gastroscopy. During gastroscopy 7 
histological samples of gastric mucosa were obtained (3 from the corpus and 4 from the 
antrum). One sample was taken for rapid urease test (CLO test, Delta West, Bentley, 
Western Australia), two samples were obtained for culture (Skirrow agar, Mueller-Hinton 
agar, E-test), and four samples for histology (Giemsa modified technique and Warthin-
Starry stains; Sydney classification system of gastritis). 
Patients were included into H. pylori positive group if the result of histology and urease 
test and in some cases of culture were positive for H. pylori. The H. pylori negative group 
included patients in whom histology, urease test and culture were negative. Histology16, 
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urease test14 and culture for H. pylori17 were done according to the previously described 
methodology. The patients who had been taking any kind of antibiotic therapy or a 
combination of antisecretory and antibiotic therapy for one month before endoscopy were 
excluded from the study.  
Serum samples were tested with commercial ELISA (Eurospital, Trieste, Italy) and CFT 
(Institute Virion, Zurich, Switzerland). The tests were performed according to the 
manufacturer's instructions. Borderline test values were established in line with the 
manufacturer's instructions, to interpret the results obtained.  
ELISA: each serum sample diluted 1:200 was applied onto a microtiter plate with 
previously bound H. pylori antigen. The antigen-antibody complex was proven by sheep 
antihuman IgG antibodies labeled with alkaline phosphatase and incubated with 
chromogen substrate. The substrate absorption was determined by ELISA reader 
(Multiscan, Titertek, MCC/340, Finland). An index of IgG antibodies equal or higher 
than 40% was considered as a positive result. 
CFT: complement fixation antibodies (IgM, IgG) were proven by H. pylori strain Lior 
type 1. Each serum sample was diluted with a 1:10 Veronal buffer and incubated for 30 
minutes at 56 °C to inactivate the complement present in the serum. Then serum sample 
as well as positive and negative serum controls were diluted from 1:10 to 1:160, edging 
certain dilution of antigen and complement. The test included controls to detect 
anticomplementary activity in each sample tested as well as control for the complement 
used (0.5, 1.0, 1.5 and 2.0 units of complement). The result of CFT was assessed on the 
basis of hemolysis inhibition. The inhibition of 50% or more was considered positive, 
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indicating the presence of antibodies in the respective dilution. Antibody titer of less than 
1:30 was considered negative. 
To determine the specificity of the serologic methods used we tested sera of 227 patients 
with pain in the upper abdomen, free from dyspeptic symptoms and without H. pylori in 
the gastric mucosa biopsy samples (histology, rapid urease test, cultures were negative) 
(Table 2). 
 
Statistics  
The χ2 test for dependent and independent samples, and the test of proportions were used. 
Statistical analysis was done by use of the Microstat software. Statistical significance was 
set at p<0.05. 
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Results  
Sensitivity and specificity of ELISA and CFT 
The sensitivity of ELISA and CFT was evaluated by testing serum samples of 276 
patients with dyspeptic symptoms. Patients underwent gastroscopy, and H. pylori was 
detected in biopsy samples by culture, CLO test and histology. The sensitivity of 
serologic methods was above 90%, i.e. 94.9% for ELISA and 93.1% for CFT (Table 2). 
The specificity of ELISA and CFT was assessed by testing serum samples of 227 patients 
free from dyspeptic symptoms and without H. pylori detected in biopsy samples of 
gastric mucosa (histology, rapid urease test, cultures were negative). The specificity of 
serologic methods was around 80%, i.e. 80.1% for ELISA and 78.4% for CFT (Table 2). 
TABLE 2. 
EVALUATION OF SENSITIVITY AND SPECIFICITY OF ELISA AND CFT  
   N    ELISA      CFT       Sensitivity         Specificity 
    n 
  + 
  n 
  - 
  n 
  + 
  n 
 - 
 ELISA 
    (%) 
CFT 
 (%) 
 ELISA 
    (%) 
  CFT 
   (%) 
H. pylori 
(+) 
276 262   14 257  19    94.9  93.1      -       - 
H. pylori 
(-) 
227   45 182   49 178       -     -    80.1     78.4 
 
N - total number of tested patients, (+) -  H. pylori positive patients, (-) -  H. pylori 
negative patients, ELISA -  enzyme-linked immunosorbent assay, CFT -  complement 
fixation test 
 
Evaluation of invasive and noninvasive serologic methods in patients with dyspeptic 
symptoms 
On the basis of gastroscopy findings, 549 patients were divided into two groups: group 1 
including patients without endoscopically verified ulcer and/or ulcer scar (168 patients 
with nonulcer dyspepsia), and group 2 including patients with ulcer and/or ulcer scar (381 
patients). 
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In all patients, biopsy samples of gastric mucosa were tested for the presence of H. pylori 
(culture, CLO test, histology). Serum samples were tested by ELISA and CFT to detect 
specific antibodies against H. pylori. Results obtained in patient sera by use of invasive 
and noninvasive methods and their evaluation are shown in Table 3. 
 TABLE 3. 
COMPARISON OF ENDOSCOPY FINDINGS WITH RESULTS OF SEROLOGIC 
AND INVASIVE METHODS IN STUDY PATIENTS 
Endoscopy 
finding 
 
 N 
   ELISA 
    n (%) 
     CFT 
    n (%) 
  Histology 
     n (%) 
   CLO 
   N (%) 
   Culture 
     n (%) 
Non-ulcer 
dyspepsia 
168 142 (84.5) 127 (75.5) 134 (79.7) 126 (75.0)   65 (38.6) 
Ulcer (scar) 
 
381 365 (95.8) 354 (92.9) 341 (89.5) 323 (84.7)  244 (64.0) 
Total 549     507       
(92.3)*/** 
     481    
(87.6)*** 
 475 (86.5)     449        
( 81.7)* 
      309   
(56.2)**/*** 
 
N - total number of patients, ELISA - enzyme-linked immunosorbent assay, CFT - 
complement fixation test, CLO - rapid urease test, *p<0.05, **p<0.001,***p<0.001 
 
A statistically significant difference between ELISA and invasive methods was only 
recorded in the group of patients with ulcer (scar) (χ2=6.45, p=0.09), however, only at a 
90% level. Comparison of CFT and invasive methods showed no statistically significant 
difference in either group of patients (χ2=6.02, ns). Comparison of ELISA and CFT 
results with the results of each individual invasive method produced a statistically 
significant difference in both groups of patients only between positive ELISA results and 
positive culture results (χ2=4.57, p<0.05). Proportion testing showed a statistically higher 
number of H. pylori infection detected in the group with ulcer (scar) by both serologic 
and invasive methods: ELISA (Z=4.59, p<0.001), CFT (Z=5.70, p<0.001), histology 
(Z=3.09, p<0.001), rapid urease test (Z=2.7, p<0.005) and culture (Z=5.23, p<0.001). 
On analysis of overall results obtained by serologic and invasive methods (Table 3) using 
the test of proportions, there was no statistically significant difference between ELISA 
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and CFT (Z=0.82, ns), or between ELISA and histology (Z=1.02, ns). However, ELISA 
showed a statistically significantly higher sensitivity than either urease test (Z=1.9, 
p<0.05) or culture (Z=7.27, p<0.001). CFT was statistically significantly more sensitive 
only compared with culture (Z=6.36, p<0.001), whereas the sensitivity of histology 
(Z=0.19, ns) and urease (Z=1.06, ns) yielded no statistically significant difference. 
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Discussion 
A variety of methods have been used in the diagnosis of H. pylori infection. Most of the 
methods are invasive because they require gastroscopy to obtain biopsy samples of 
gastric mucosa for further analysis and detection of H. pylori infection. Culture is 
necessary to test for antimicrobial susceptibilities. The other group of methods are 
noninvasive because they do not require gastroscopy and H. pylori infection can be 
detected by the presence of antibodies in serum samples (serology), by the presence of 
labeled CO2 in exhaled breath upon ingestion of labeled urea, and by the bacterial urease 
activity (urea breath test). 
ELISA is most widely used in the detection (qualitative) and measurement (quantitative) 
of the level of specific antibodies in serum samples. The previously used non-purified 
antigens have been replaced by purified products of urease and/or proteins of great 
molecular mass extracted from glycine. Immunoblot (Western blot) has recently been 
used as the method of choice for evaluation of immunity response against different H. 
pylori antigens (VacA, CagA). Antibodies against these antigens indicate an increased 
risk of ulcer and gastric adenocarcinoma, and are used as a confirmation test for the 
results obtained by other serologic methods24-26. ELISA detects the presence of individual 
classes of specific antibodies and can also determine the level of these antibodies in 
serum samples. ELISA tests for the detection of IgG antibodies have a more than 90% 
sensitivity and specificity27. The sensitivity of serologic methods used in the present 
study was more than 90%. The sensitivity of ELISA was 94.9%, exceeding the sensitivity 
of CFT of 93.1%. The specificity was slightly lower: 80.1% for ELISA and 78.4% for 
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CFT, which is consistent with the results reported elsewhere for commercial serologic 
procedures28,29.  
The sensitivity and specificity are important parameters which show the purpose of using 
serologic methods in the diagnosis of H. pylori and evaluation of the methods employed. 
Different values of the sensitivity and specificity reported from various studies could be 
explained by the use of different normal values and "standard" methods. Some studies 
employed only one noninvasive method (culture, histology or rapid urease test) as a 
standard method, whereas others employed a combination of two or more methods. In 
our study, we chose histology, culture and rapid urease test as standard methods. 
The sensitivity and specificity of the superior serologic tests are the same as the 
sensitivity and specificity of urea breath test30. The sensitivity of serologic tests is slightly 
higher than the sensitivity of invasive methods31,32, as confirmed by our results. In the 
group of patients with ulcer and/or ulcer scar, a statistically significant difference was 
recorded in the detection of infection between ELISA (at 90% level) and invasive 
methods. The difference in sensitivity between serologic and invasive methods may be 
caused by difficulty in obtaining biopsy material due to the poorly visible site of H. pylori 
colonization on the gastric mucosa32-36 and the effect of antibacterial therapy. Some 
authors37,38 emphasize a disproportion between the grade of infection and the degree of 
immune response, pointing to inter-individual differences in the immune response to 
infection. There are literature reports on cases of H. pylori infection detected by invasive 
methods yet not accompanied by corresponding antibody levels, which results from a 
weak or absent response of the immune system39,40. In atrophic gastritis, serology may be 
the only tool to detect H. pylori infection41-43. In addition, invasive tests do not perform 
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well in patients with bleeding ulcers44-46. It should be noted that the sensitivity and 
specificity of serologic methods are reduced in persons above 60 years of age as the 
result of weak immune response47.  
The incidence of H. pylori negative "nonspecific gastritis" is higher in the elderly, which 
may be due to the small number of bacteria present in gastric mucosa, previous infection 
treated with antibiotics, gastric mucosa atrophy, and gastritis of other etiology 
(autoimmune gastritis, prolonged therapy with nonsteroidal anti-inflammatory drugs). 
Like serologic methods, histologic methods also are less reliable in detecting H. pylori 
infection in the elderly. Tests for antibody detection in saliva samples have a lower 
sensitivity and specificity than tests for the detection of serum antibodies48,49. 
In spite of these shortcomings associated with serologic methods, simultaneous usage of 
a serologic method with one or more invasive methods will significantly increase the 
overall sensitivity of the diagnostic work-up. This is important in patients with clinical 
signs of severe infection and in those aged >45, who are at a higher risk of developing 
serious complications. Some authors suggest that patients younger than 45 without 
alarming symptoms can be screened for the presence of infection using only serologic 
methods50. Today, the recommendation is to use more methods for detecting H. pylori 
infection because all known methods yield some 5%-10% of false positive or false 
negative results51. 
Our results showed the use of serologic methods in the detection of H. pylori infection 
(primary infection) with commercial CFT and ELISA tests to be helpful, reliable and 
fully justified. Commercial products were evaluated by testing the sera from a selected 
patient population. The sensitivity, specificity and reference values were determined, as 
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they differ from population to population. Three standard methods, i.e. histology, culture 
and urease test, were used on evaluation of the serologic method sensitivity and 
specificity. The sensitivity of serologic methods exceeded 90%; however, ELISA showed 
higher sensitivity and specificity than CFT (94.9% vs 93.1% and 80.1% vs 78.4%, 
respectively). 
 
 16 
 
REFERENCES 
1. VELDHUYZEN VAN ZANTEN, S. J., P. M. SHERMAN, CMAJ, 150 (1994) 177. – 
2. PETERSON, W. L., N. Engl. J. Med., 324 (1991) 1043. – 3. GRAHAM, D. Y. J., 
Gastroenterol. Hepatol., 6 (1991) 105. – 4. HARRIS, A., J. J. MISIEWICZ, BMJ, 323 
(2001) 1047. – 5. CALAM, J., J. H. BARON, BMJ, 323 (2001) 980. – 6. KATIČIĆ. M., 
V. PRESEČKI: Helicobacter pylori izazov za medicinu. (MGC, Zagreb, 1996). – 7. 
PARSONNET, J., N. Engl. J. Med., 335 (1996) 278. – 8. STRNAD, M., V. PRESEČKI, 
V. BABUŠ, A. TUREK, M. DOMINIS, S. KALENIĆ, A. HEBRANG, M. KATIČIĆ, 
Lijec. Vjesn., 124 (Suppl 1) (2002) 5. – 9. BANIĆ, M., M. BULJEVAC, M. 
KUJUNDŽIĆ, D. JELIĆ, M. DOMINIS, V. ČOLIĆ-CVRLJE, D. KARDUM, M. 
KATIČIĆ, Lijec. Vjesn., 124 (Suppl. 1) (2002) 63. – 10. DANESH, J., A. 
GASBARRINI, F. CREMONINI, G. GASBARRINI, Curr. Opin. Gastroenterol., 16 
(Suppl. 1) (2000) 52. – 11. YAMADA, T.: Textbook of Gastroenterology. (Lippincott 
Company, Philadelphia, 1991). – 12. BROWN, K. E., D. A. PEURA, Gastroenterol. Clin. 
North. Am., 22 (1993) 105. – 13. KATIČIĆ, M., V. PRESEČKI, S. KALENIĆ, M. 
DOMINIS, T. FILIPEC, B. PAPA, Lijec. Vjesn., 124 (Suppl. 1) (2002) 16. – 14. 
FILIPEC, T., M. PRSKALO, M. TIĆAK, B. ŠABARIĆ, B. ŠKURLA, B. PAPA, V. 
ČOLIĆ-CVRLJE, S. NAUMOVSKI-MIHALIĆ, M. MARUŠIĆ, M. KATIČIĆ, Lijec. 
Vjesn., 124 (Suppl 1) (2002) 33. – 15. KALENIĆ, S., M. DOMINIS, V. PRESEČKI, 
Medicus, 5 (1996) 27. – 16. DOMINIS, M., S. DŽEBRO, S, GAŠPAROV, M. 
BULJEVAC, V. ČOLIĆ-CVRLJE, M. BANIĆ, M. KATIČIĆ, Lijec. Vjesn., 124 (Suppl. 
1) (2002) 36. – 17. PLEČKO, V., S. KALENIĆ, V. PRESEČKI, M. DOMINIS, M. 
 17 
KATIČIĆ, Lijec. Vjesn., 124 (suppl. 1) (2002) 20. – 18. LOGAN, R. P., S. DILL, F. E. 
BAUER, Eur. J. Gastroenterol. Hepatol., 3 (1991) 915. – 19. FILIPEC, T., M. KATIČIĆ, 
B. PAPA, V. ČOLIĆ-CVRLJE, M. PRSKALO, M. TIĆAK, B. ŠABARIĆ, S. 
NAUMOVSKI-MIHALIĆ, B. ŠKURLA, Lijec. Vjesn., 124 (Suppl. 1) (2002) 28. – 20. 
KOSUNEN, T. U., K. SEPPALA, S. SARNA, P. SIPPONEN, Lancet, 339 (1992) 893. – 
21. PRESEČKI, V., M. KATIČIĆ, M. MARUŠIĆ, S. KALENIĆ, M. STRNAD, M. 
PLEČKO, V. BABUŠ, M. DOMINIS, Lijec. Vjesn., 124 (Suppl. 1) (2002) 23. – 22. 
KOSUNEN, T. U., F. MEGRAUD, Curr. Opin. Gastroenterol., 11 (Suppl. 1) (1995) 5. – 
23. GRAHAM, D. Y., H. M. MALATY, D. G. EVANS, D. J. EVANS, P. D. KLEIN, E. 
ADAM, Gastroenterology, 100 (1991) 1495. – 24. RUDI, J., C. KOLB, M. MAIWALD, 
I. ZUNA, A. VON HERBAZ, P. R. GALLE, W. STREMMEL, Dig. Dis. Sci., 42 (1997) 
1652. – 25. TORRO RUEDA, C., J. GARCIA-SAMANIEGO, I. CASADO FARINAS, 
M. RUBIO ALONSO, M. BAQUERO MOCHALES, Rev. Clin. Esp., 203 (2003) 430. – 
26. SOZZI, M., M. VALENTINI, N. FIGURA, P. DE POLI, R. M. TEDESCHI, A. 
GLOGHINI, D. SERRAINO, M. POLLETI, Am. J. Gastroenterol., 93 (1998) 375. – 27. 
FELDMAN, R. A., J. J. DEEKS, S. J. EVANS, Eur. J. Clin. Microbiol. Infect. Dis., 14 
(1995) 428. – 28. BREA, M. L., T. ALARCON, F. MEGRAUD, Curr. Opin. 
Gastroenterol., 13 (Suppl. 1) (1997) 13. – 29. VOROBJOVA, T., H. I. MAAROOS, R. 
UIBO, T. WADSTROM, W. G. WOOD, P. SIPPONEN, Scand. J. Gastroenterol., 26 
(Suppl. 186) (1991) 84. – 30. ATHERON, J. C., R. C. SPILLER, Gut, 35 (1994) 723. – 
31. THIJS, J. C., A. A. VAN ZWET, W. J. THIJS, H. B. OEY, A. KARRENBELD, F. 
STELLAARD, D. S. LUIJT, B. C. MEYER, J. H. KLEIBEUKER, Am. J. Gastroenterol., 
91 (1996) 2125. – 32. CUTLER, A. F., S. JAVSTAD, C. K. MA, M. J. BLASER, G. I. 
 18 
PEREZ-PEREZ, T. T. SCHUBERT, Gastroenterology, 109 (1995) 136. – 33. BOLTON, 
F. J., D. N. HUTCHINSON, J. Clin. Pathol., 42 (1989) 723. – 34. MORRIS, A., M. R. 
ALI, P. BROWN, M. LANE, K. PATTON, J. Clin. Pathol., 42 (1989) 727. – 35. 
MORRIS, A. J., M. R. ALI, G. I. NICHOLSON, G. I. PEREZ-PEREZ, M. J. BLASER, 
Ann. Intern. Med., 114 (1991) 662. – 36. FRASER, A. G., J. BICKLEY, R. J. OWEN, R. 
E. POUNDER, J. Clin. Pathol., 45 (1992) 1062. – 37. THIJS, J. C., A. A. YWET, B. C. 
MEYER, R. J. P. BERRELKAMP, Eur. J. Gastroenterol. Hepatol., 6 (1994) 579. – 38. 
SODEBERG, M., L. ENGSTRAND, M. STROM, K. A. JONSSON, H. JORBECK, M. 
GRANDSTROM, Scand. J. Infect. Dis., 29 (1997) 147. – 39. MEGRAUD, F., Scand. J. 
Gastroenterol., 31 (Suppl. 215) (1996) 57. – 40. HIRSCHL, A. M., G. 
BRANDSTATTER, B. DRAGOSICS, E. HEMTSCHEL, R. KUNDI, M. L. ROTTER, 
K. SCHUTZE, M. TAUFER, J. Infect. Dis., 168 (1993) 763. – 41. KOKKOLA, A., H. 
RAUTELIN, P. PUOLAKKAINEN, P. SIPPONEN, M. FARKKILA, R. HAAPIAINEN, 
T. U. KOSUNEN, Scand. J. Gastroenterol., 35 (2) (2000) 138. – 42. LAHNER, W., D. 
VAIRA, N. FIGURA, E. PILOZZI, A. PASQUALI, C. SEVERI, F. PEMA, G. DELLE 
FAVE, B. ANNIBALE, Helicobacter, 9 (5) (2004) 436. – 43. KUIPERS, E., Eur. J. 
Gastroenterol. Hepatol., 15 (8) (2003) 877. – 44. LO, C. C., K. H. LAI, N. J. PENG, G. 
H. LO, H. H. TSENG, C. K. LIN, C. B. SHIE, C. M. WU, Y. S. CHEN, W. K. HUANG, 
A. CHEN, O. I. HSU, World J. Gastroenterol., 11 (25) (2005) 3909. – 45. CASTRO-
FERNANDEZ, M., D. SANCHEZ-MUNOZ, E. GARCIA-DIAZ, J. MIRALLES-
SANCHIZ, J. VARGAS-ROMERO, Rev. Esp. Enferm. Dig., 96 (6) (2004) 395. – 46. 
PEITZ, U., A. LEODOLTER, T. WEX, D. SCHUTZE, K. WOLLE, T. WELTE, T. 
GUNTHER, U. SCHMIDT, P. MALFERTHEINER, Gastroenterol., 42 (2) (2004) 141. – 
 19 
47. WYATT, J. I., T. M. SHALLCROSS, J. E. CRABTREE, R. V. HEATLEY, J. Clin. 
Pathol., 45 (1992) 1070. – 48. MOAYYEDI, P., D. S. TOMPKINS, A. T. AXON, 
Lancet, 344 (1994) 1016. – 49. CHRISTIE, J. M., C. A. MCNULTY, N. A. SHEPHERD, 
R. M. VALORI, Gut, 39 (1996) 27. – 50. SOBALA, G. M., J. E. CRABTREE, J. A. 
PENTITH, B. J. RATHBONE, T. M. SHALLCROSS, J. I. WYATT, M. F. DIXON, R. 
V. HEATLEY, A. T. AXON, Lancet, 338 (1991) 96. – 51. BOER, W. A., L. LAAT, F. 
MEGRAUD, Curr. Opin. Gastroenterol., 16 (Suppl. 1) (2000) 5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 20 
Corresponding author's address  
M. Marušić 
University Department of Medicine, General Hospital” Sveti Duh”, Sveti Duh 64, 10000 
Zagreb, Croatia 
e-mail: marinko.marusic1@zg.t-com.hr 
 
 21 
 
MJESTO I ULOGA SEROLOŠKIH METODA U UTVRĐIVANJU INFEKCIJE 
HELICOBACTER PYLORI  
 
SAŽETAK 
Cilj nam je bio na temelju utvrđenih vrijednosti osjetljivosti i specifičnosti metoda 
ELISA (imunoenzimski test) i reakcije vezanja komplementa odrediti mjesto i značenje 
seroloških metoda u otkrivanju infekcije Helicobacter pylori (H. pylori). U ispitivanje je 
bilo uključeno 549 bolesnika, a navedene serološke metode su uspoređene s invazivnim 
metodama (CLO test, izolacija, histološki pregled). Osjetljivost seroloških metoda 
premašila je 90%, dok je specifičnost bila približno 80%. Ovim radom je dokazana 
vrijednost, pouzdanost i opravdanost uporabe seroloških postupaka u otkrivanju infekcije 
H. pylori. 
 
 
 
